Sensorion is a biotech spinoff founded within Inserm in 2009 that focuses on treatments for inner ear pathologies such as acute vertigo, tinnitus and progressive hearing loss. The company has developed a technological platform centered on hair‑cell biology to identify and test symptomatic and anti‑lesional drug candidates. Its lead candidate, SENS‑111, is intended to treat bouts of vertigo or tinnitus; a second programme targeting progressive inner‑ear lesions is also advancing toward clinical testing. Sensorion plans to start a 1b clinical trial for SENS‑111 in Q1 2015 and to select a second drug candidate for clinical development. The company employs 15 staff, holds a portfolio of seven patent families, and reports financial backing from Bpifrance and Inserm Transfert Initiative. Financially, Sensorion completed a milestone‑based funding round of up to €4 million that brings total funds raised since its 2009 founding to €10 million. Sensorion develops innovative and targeted therapeutic solutions to treat vestibular deficits, including novel vestibuloplegics intended to relieve vertigo symptoms. The company aims to protect and restore vestibular function through its therapeutic programs. Founded in June 2009 by four scientists, Sensorion is a spin-off of the Pathophysiology and Therapy of Vestibular Deficits research team (INSERM U583). Its research base is at the Montpellier Neuroscience Institute on the Gui de Chauliac Hospital campus. Sensorion recently raised €750K in funding to reinforce its development capacities. The investment was made by CDC Entreprises via InnoBio under the FSI France Investissement program.

Total raised

$6M

Funding rounds

2

Latest round

Equity

Latest activity

Jan 2015